Eckelman Brendan P. 4
4 · Inhibrx, Inc. · Filed Mar 12, 2024
Insider Transaction Report
Form 4
Inhibrx, Inc.INBX
Eckelman Brendan P.
DirectorChief Scientific Officer10% Owner
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2024-03-11$35.30/sh−6,877$242,761→ 30,973 totalExercise: $33.63Exp: 2021-01-15→ Common Stock (6,877 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-03-08$35.75/sh−2,150$76,863→ 37,850 totalExercise: $33.63Exp: 2021-01-15→ Common Stock (2,150 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-03-11$35.33/sh−6,681$236,066→ 33,319 totalExercise: $23.30Exp: 2033-01-03→ Common Stock (6,681 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-03-12$35.25/sh−4,152$146,359→ 29,167 totalExercise: $23.30Exp: 2033-01-03→ Common Stock (4,152 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-03-12$35.25/sh−19,898$701,498→ 11,075 totalExercise: $33.63Exp: 2021-01-15→ Common Stock (19,898 underlying)
Footnotes (5)
- [F1]Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
- [F2]The stock options were exercised in multiple transactions at prices ranging from $35.2927 to $35.3104, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F3]Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
- [F4]The stock options were exercised in multiple transactions at prices ranging from $35.25 to $35.325, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F5]The stock options were exercised in multiple transactions at prices ranging from $35.25 to $35.27, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.